Allovir, INC 10-Q quarterly reports

Kalaris Therapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses and a strong reliance on future financing, while advancing its lead drug candidate TH103.

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported Q3 2025 financial results, highlighting progress in its TH103 clinical trials and a strengthened cash position following its merger with AlloVir.

Kalaris Therapeutics reports increased losses and cash burn in Q2 2025, despite a significant cash infusion from its merger with AlloVir, as it advances its lead retinal disease candidate TH103.

Kalaris Therapeutics reports its first quarterly results post-merger with AlloVir, highlighting key executive employment agreements and ongoing clinical trial developments.

AlloVir, a clinical-stage cell therapy company, has entered into a merger agreement with Kalaris Therapeutics after discontinuing Phase 3 trials and undergoing a strategic review.

AlloVir, a clinical-stage cell therapy company, released its Q2 2024 financial results, highlighting a significant reduction in operating expenses due to the discontinuation of clinical trials and a strategic review process.

AlloVir, a clinical-stage cell therapy company, announced its first quarter 2024 financial results, highlighting a significant reduction in operating expenses due to a strategic review and workforce reduction.